

# **Infutec Healthcare Limited**

April 25, 2025

Facilities/Instruments	Amount (₹ crore)	Rating <sup>1</sup>	Rating Action
Long Term Bank Facilities	49.09	CARE D; ISSUER NOT COOPERATING*	Rating continues to remain under ISSUER NOT COOPERATING category
Long Term / Short Term Bank Facilities	14.50	CARE D / CARE D; ISSUER NOT COOPERATING*	Rating continues to remain under ISSUER NOT COOPERATING category

Details of instruments/facilities in Annexure-1.

## Rationale and key rating drivers

CARE Ratings Ltd. had, vide its press release dated April 16, 2024, placed the rating(s) of Infutec Healthcare Limited (IHL) under the 'issuer non-cooperating' category as IHL had failed to provide information for monitoring of the rating as agreed to in its Rating Agreement. IHL continues to be non-cooperative despite repeated requests for submission of information through e-mails dated March 02, 2025, March 12, 2025, March 22, 2025 among others.

In line with the extant SEBI guidelines, CARE Ratings Ltd. has reviewed the rating on the basis of the best available information which however, in CARE Ratings Ltd.'s opinion is not sufficient to arrive at a fair rating.

Users of this rating (including investors, lenders and the public at large) are hence requested to exercise caution while using the above rating(s).

Analytical approach: Standalone

Outlook: Not Applicable

## **Detailed description of the key rating drivers:**

Please refer to PR dated April 16, 2024

### Applicable criteria

Policy in respect of Non-cooperation by Issuer Policy on Default Recognition

## **About the company**

IHL (erstwhile Goa Formulations Ltd, CIN: U24230MH2005PLC155962) was a wholly owned subsidiary of Indore-based Parental Drugs India Limited (PDIL). As on July 10, 2018, one of the investors i.e. Mahaganpati Investment Private Limited (MIPL) converted preference share of Rs.48.50 crore (book value) into equity share leading to dilution of the shareholding of PDIL. As on March 31, 2021, PDIL holds 12.24% equity stake in the company whereas the majority holding of 87.76% equity stake is held by MIPL. IHL is engaged in manufacturing of pharmaceutical products mainly into intravenous fluids at its plant located at Hoshiarpur, Punjab.

Status of non-cooperation with previous CRA: Not Applicable

Any other information: Not Applicable

Rating History for last three years: Annexure-2

Covenants of rated instrument / facility: Annexure-3

Complexity level of various instruments rated: Annexure-4

Lender details: Annexure-5

<sup>1</sup>Complete definition of ratings assigned are available at <a href="www.careedqe.in">www.careedqe.in</a> and other CARE Ratings Limited's publications.

1 CARE Ratings Ltd.

<sup>\*</sup>Issuer did not cooperate; based on best available information.



**Annexure-1: Details of instruments/facilities** 

Name of the Instrument	ISIN	Date of Issuance (DD- MM-YYYY)	Coupon Rate (%)	Maturity Date (DD- MM-YYYY)	Size of the Issue (₹ crore)	Rating Assigned and Rating Outlook
Fund-based - LT-Cash Credit		-	-	-	25.00	CARE D; ISSUER NOT COOPERATING*
Fund-based - LT-Term Loan		-	-	30/03/2025	24.09	CARE D; ISSUER NOT COOPERATING*
Non-fund- based - LT/ ST- BG/LC		-	-	-	14.50	CARE D / CARE D; ISSUER NOT COOPERATING*

<sup>\*</sup>Issuer did not cooperate; based on best available information.

Annexure-2: Rating history for last three years

		Current Ratings			Rating History			
Sr. No	Name of the Instrument/Ban k Facilities	Туре	Amount Outstandin g (₹ crore)	Rating	Date(s) and Rating(s ) assigned in 2025- 2026	Date(s) and Rating(s) assigned in 2024-2025	Date(s) and Rating(s ) assigned in 2023- 2024	Date(s) and Rating(s) assigned in 2022-2023
1	Fund-based - LT- Term Loan	LT	24.09	CARE D; ISSUER NOT COOPERATING *	-	1)CARE D; ISSUER NOT COOPERATING * (16-Apr-24)	1	1)CARE D; ISSUER NOT COOPERATING * (31-Jan-23)
2	Fund-based - LT- Cash Credit	LT	25.00	CARE D; ISSUER NOT COOPERATING *	-	1)CARE D; ISSUER NOT COOPERATING * (16-Apr-24)	-	1)CARE D; ISSUER NOT COOPERATING * (31-Jan-23)
3	Non-fund-based - LT/ ST-BG/LC	LT/S T	14.50	CARE D / CARE D; ISSUER NOT COOPERATING *	-	1)CARE D / CARE D; ISSUER NOT COOPERATING * (16-Apr-24)	1	1)CARE D / CARE D; ISSUER NOT COOPERATING * (31-Jan-23)

<sup>\*</sup>Issuer did not cooperate; based on best available information.

# Annexure-3: Detailed explanation of covenants of rated instruments/facilities: Not Applicable

**Annexure-4: Complexity level of instruments rated** 

Sr. No.	Name of the Instrument	Complexity Level	
1	Fund-based - LT-Cash Credit	Simple	
2	Fund-based - LT-Term Loan	Simple	
3	Non-fund-based - LT/ ST-BG/LC	Simple	

## **Annexure-5: Lender details**

To view the lender wise details of bank facilities please click here

**Note on complexity levels of rated instruments:** CARE Ratings has classified instruments rated by it based on complexity. Investors/market intermediaries/regulators or others are welcome to write to care@careedge.in for clarifications.

2 CARE Ratings Ltd.

LT: Long term; LT/ST: Long term/Short term



### Contact us

**Media Contact** 

Mradul Mishra Director

**CARE Ratings Limited** Phone: +91-22-6754 3596

E-mail: mradul.mishra@careedge.in

**Relationship Contact** 

Ankur Sachdeva Senior Director

CARE Ratings Limited Phone: 912267543444

E-mail: Ankur.sachdeva@careedge.in

**Analytical Contacts** 

Shachee Nakul Vyas Assistant Director

CARE Ratings Limited

Phone: 079-40265665

E-mail: <a href="mailto:shachee.tripathi@careedge.in">shachee.tripathi@careedge.in</a>

Jekin Shah Analyst

CARE Ratings Limited Phone: 079-40265679

E-mail: Jekin.Shah@careedge.in

Riddhi Virenkumar Shah

Analyst

**CARE Ratings Limited** 

E-mail: riddhi.shah@careedge.in

### **About us:**

Established in 1993, CARE Ratings is one of the leading credit rating agencies in India. Registered under the Securities and Exchange Board of India, it has been acknowledged as an External Credit Assessment Institution by the RBI. With an equitable position in the Indian capital market, CARE Ratings provides a wide array of credit rating services that help corporates raise capital and enable investors to make informed decisions. With an established track record of rating companies over almost three decades, CARE Ratings follows a robust and transparent rating process that leverages its domain and analytical expertise, backed by the methodologies congruent with the international best practices. CARE Ratings has played a pivotal role in developing bank debt and capital market instruments, including commercial papers, corporate bonds and debentures, and structured credit.

### Disclaimer:

The ratings issued by CARE Ratings are opinions on the likelihood of timely payment of the obligations under the rated instrument and are not recommendations to sanction, renew, disburse, or recall the concerned bank facilities or to buy, sell, or hold any security. These ratings do not convey suitability or price for the investor. The agency does not constitute an audit on the rated entity. CARE Ratings has based its ratings/outlook based on information obtained from reliable and credible sources. CARE Ratings does not, however, guarantee the accuracy, adequacy, or completeness of any information and is not responsible for any errors or omissions and the results obtained from the use of such information. Most entities whose bank facilities/instruments are rated by CARE Ratings have paid a credit rating fee, based on the amount and type of bank facilities/instruments. CARE Ratings or its subsidiaries/associates may also be involved with other commercial transactions with the entity. In case of partnership/proprietary concerns, the rating/outlook assigned by CARE Ratings is, inter-alia, based on the capital deployed by the partners/proprietors and the current financial strength of the firm. The ratings/outlook may change in case of withdrawal of capital, or the unsecured loans brought in by the partners/proprietors in addition to the financial performance and other relevant factors. CARE Ratings is not responsible for any errors and states that it has no financial liability whatsoever to the users of the ratings of CARE Ratings. The ratings of CARE Ratings do not factor in any rating-related trigger clauses as per the terms of the facilities/instruments, which may involve acceleration of payments in case of rating downgrades. However, if any such clauses are introduced and triggered, the ratings may see volatility and sharp downgrades.

3 CARE Ratings Ltd.